Solid Biosciences SLDB
NASDAQ SLDB
$7.17 +0.15 (+2.14%)
At close: Nov 10, 2026 · 4:00 PM EST

Solid Biosciences (SLDB) Revenue (2021 - 2022)

Updated

Solid Biosciences' Revenue was $8.09 million in FY2022, down 40.6% from $13.62 million in FY2021.

Analysis

Solid Biosciences (SLDB) Revenue (2021 - 2022) Analysis & Trends

  • Per Business Quant data, Revenue in earlier years was $13.62 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 24.40 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 25.40 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 17.40 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 18.09 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 15.38 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 10.37 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 8.30 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 16.58 Bn
10 Solid Biosciences 1.08 Bn -216.77 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 6.17 Mn
Jun 30, 2021 -13,000.00
Mar 31, 2021 -14,000.00
API Access

Solid Biosciences Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=SLDB&period=max&api_key=YOUR_API_KEY